AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth

AngioDynamics Inc. (NASDAQ:ANGO) shares declined 4.26% in pre-market trading after the medical technology company reported first-quarter fiscal 2027 results that exceeded analysts’ expectations, supported by continued growth in its Med Tech business and improving profitability.

The company reported an adjusted loss of $0.04 per share, narrower than the Wall Street consensus estimate of a loss of $0.11 per share.

Quarterly revenue reached $80.9 million, slightly above analysts’ expectations of $80.5 million, representing a 6.9% increase from the corresponding period a year earlier.

The revenue improvement was primarily driven by the Med Tech segment, which recorded 13.2% year-on-year growth to $39.9 million.

This marked the eighth consecutive quarter in which the division achieved double-digit revenue growth, reflecting sustained demand for its specialised medical technologies.

Meanwhile, the Med Device segment generated revenue of $41.0 million, an increase of 1.4% compared with the prior-year quarter.

AngioDynamics also reported an improvement in gross profitability, with its gross margin expanding by 410 basis points to 59.4%.

However, the company noted that the margin increase included a benefit from tariff refunds received during the quarter.

Auryon and NanoKnife Support Med Tech Revenue Growth

The Med Tech division continued to lead AngioDynamics’ performance, with growth across its Auryon, Mechanical Thrombectomy and NanoKnife product lines.

Auryon, the company’s atherectomy technology platform, generated revenue of $18.9 million, representing a 14.7% increase year on year.

The product line recorded its 21st consecutive quarter of double-digit growth in atherectomy sales.

Mechanical Thrombectomy revenue increased 6.7% to $12.0 million, reflecting continued demand for the company’s clot-removal technologies.

NanoKnife delivered the strongest percentage growth among the three product categories, with sales rising 29.0% to $8.3 million.

The increase was supported by demand for prostate procedures using the company’s oncology technology.

President and Chief Executive Officer Jim Clemmer attributed the quarterly performance to consistent execution across the business.

“Our first quarter results reflect the continued, consistent execution we’ve built into this business,” Clemmer said.

“Med Tech again led our growth, highlighted by Auryon’s 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”

The results demonstrated the importance of the company’s higher-growth Med Tech portfolio in supporting overall revenue expansion.

AngioDynamics Narrows Net Loss and Improves Adjusted EBITDA

AngioDynamics reported a net loss under generally accepted accounting principles (GAAP) of $7.1 million, equivalent to $0.17 per share.

This compared with a GAAP net loss of $10.9 million, or $0.26 per share, in the corresponding quarter of fiscal 2026.

The reduction in losses reflected an improvement in the company’s financial performance alongside higher revenue.

Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) increased to $5.0 million from $2.2 million a year earlier.

The improvement in adjusted EBITDA indicated stronger operating profitability, although the reported gross margin benefited partly from the tariff refunds.

The company continues to focus on expanding its Med Tech business while managing costs across its broader product portfolio.

Fiscal 2027 Revenue and Earnings Guidance Reaffirmed

Despite the decline in its share price, AngioDynamics maintained its financial guidance for fiscal 2027.

The company continues to expect full-year revenue of between $336 million and $341 million.

The midpoint of the guidance range, $338.5 million, is slightly above the analyst consensus estimate of $337.32 million.

AngioDynamics also reaffirmed its adjusted earnings outlook, forecasting a loss of between $0.29 and $0.24 per share for the full year.

The midpoint of this range represents an expected adjusted loss of approximately $0.265 per share.

The unchanged guidance suggests that management’s expectations for the remainder of the financial year remain consistent with its previous outlook.

Investors will be monitoring whether continued growth in the Med Tech segment can support further improvements in margins and operating profitability.

Eric Honroth to Succeed Jim Clemmer as CEO in November

Alongside its quarterly financial results, AngioDynamics announced a leadership transition scheduled for 2 November 2026.

Eric Honroth will become President and Chief Executive Officer, succeeding Jim Clemmer, who is retiring after ten years with the company.

The appointment marks a change in leadership as AngioDynamics continues developing its Med Tech portfolio and pursuing its fiscal 2027 financial objectives.

The company enters the transition following another quarter of double-digit Med Tech growth, improving adjusted EBITDA and a narrower net loss.

Although its financial results exceeded market expectations, AngioDynamics shares moved lower in pre-market trading as investors assessed the quarterly performance, the contribution of tariff refunds to margins and the company’s unchanged full-year outlook.

AngioDynamics stock price